Physician profile
Cameron Ghaffary
NPI 1629498159
$6,549.58
in general payments reported to CMS, 2019-2025
26 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,185 · 2020: $487 · 2021: $747 · 2022: $859 · 2023: $718 · 2024: $858 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.07 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,865.53 | 2019-2020 | |
| Astellas Pharma US INC | $894.65 | 2019-2025 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $849.05 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $632.47 | 2023-2025 | Orgovyx |
| Abbvie INC. | $446.80 | 2023-2025 | |
| Coloplast Corp | $275.84 | 2020-2023 | Porges Coloplast |
| Myovant Sciences INC. | $249.27 | 2021-2022 | |
| Teleflex LLC | $215.00 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $200.74 | 2019-2022 | |
| Urogen Pharma, INC. | $161.24 | 2022-2024 | Jelmyto |
| Endo Pharmaceuticals INC. | $153.45 | 2020-2022 | |
| Agiliti Surgical, INC. | $97.32 | 2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Pfizer INC. | $86.16 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $85.41 | 2024-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $70.08 | 2019-2024 | Provenge |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $52.02 | 2023-2025 | Erleada, Akeega |
| Endo USA, INC. | $50.49 | 2024-2025 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $24.76 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.83 | 2021 | |
| Myriad Genetic Laboratories, INC. | $21.75 | 2025 | Prolaris |
| Tolmar, INC. | $21.39 | 2023 | |
| Merck Sharp & Dohme LLC | $19.75 | 2024 | Keytruda |
| Immunitybio, INC. | $19.49 | 2024 | |
| Allergan, INC. | $13.99 | 2019 | |
| Healthtronics Stone Solutions, LLC | $10.65 | 2024 | Dornier Medtech |
| Travere Therapeutics, INC. | $9.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Ghaffary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.